^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ad-CCL21-DC

    i
    Associations
    News

    Trials

    Company:
    National Cancer Institute
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer (HEMONC CIRM IST Lung) (NCT03546361)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    01/14/2025
    Initiation :
    07/08/2019
    Primary completion :
    01/11/2026
    Completion :
    01/11/2027
    PD-L1
    |
    EGFR mutation • EGFR T790M • ALK rearrangement
    |
    Keytruda (pembrolizumab) • Ad-CCL21-DC
    Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NCT00601094)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Completed
    Last update posted :
    08/03/2020
    Initiation :
    02/26/2009
    Primary completion :
    05/23/2017
    Completion :
    05/23/2017
    IFNG
    |
    Ad-CCL21-DC